Rezafungin noninferior to standard antifungal prophylaxis regimen after allogeneic HSCT

một ngày trước
Elaine Soliven
Elaine SolivenEditor; MIMS
Elaine Soliven
Elaine Soliven Editor; MIMS
Rezafungin noninferior to standard antifungal prophylaxis regimen after allogeneic HSCT

Once-weekly rezafungin is noninferior to a daily standard antimicrobial regimen (SAR) for preventing invasive fungal disease (IFD) in adult patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), according to the phase III ReSPECT trial presented at IDWeek 2026.

At day 90 following allo-HSCT, the primary endpoint of fungal-free survival (FFS), defined as a composite of survival, absence of proven or probable IFD, and no use of nonstudy systemic antifungal therapy for >10 cumulative days, was achieved by 60.7 percent of patients in the rezafungin group compared with 59 percent in the SAR group. [Maertens J, et al, IDWeek 2026]

This corresponded to a treatment difference of –1.6 percentage points (95 percent confidence interval [CI], –6.2 to 9.3), meeting the prespecified criteria for noninferiority (p<0.001), said Dr Shariq Haider from Juravinski Hospital and Cancer Center, McMaster University, Hamilton, Ontario, Canada.

These findings were further supported by six prespecified sensitivity analyses, he noted.

In this multicentre, double-blind, phase III trial, 602 patients undergoing allo-HSCT were randomized in a 2:1 ratio to receive either weekly intravenous rezafungin* (n=402) or daily oral SAR (azole** [fluconazole or posaconazole] plus trimethoprim/sulfamethoxazole [TMP/SMX]***; n=200) for 13 weeks. Patients receiving fluconazole who developed acute graft-vs-host disease were allowed to switch permanently to posaconazole. Baseline characteristics were similar in both groups.

At day 90, most FFS failures were driven by the use of nonstudy systemic antifungal therapy for >10 days, which was numerically lower in the rezafungin group than in the SAR group (27.4 percent vs 32.5 percent).

Other components that contributed to FFS failure occurred at similarly low rates in the rezafungin and SAR groups, including deaths (4.5 percent vs 5.5 percent) and proven or probable IFD (3.5 percent vs 4.5 percent).

Notably, the incidence of breakthrough invasive fungal infections, particularly Candida spp. and Pneumocystis jirovecii, was low and comparable in both groups, aligning with the expected reduction in breakthrough IFD with SAR prophylaxis, according to Haider.

In terms of safety, the overall rates of treatment-emergent adverse events (TEAEs) were comparable between the rezafungin and SAR groups (99.7 percent vs 100 percent), as were the rates of serious AEs (66 percent vs 67.5 percent).

By contrast, the incidence of TEAEs leading to study drug dose reduction, interruption, or withdrawal was lower with rezafungin than with SAR (31 percent vs 47.7 percent), a difference primarily driven by fewer events of acute kidney injury in the rezafungin group (5.5 percent vs 10.2 percent).

“Rezafungin had a favourable renal safety profile compared with SAR, with no new safety signals identified in allo-HCT recipients,” Haider noted.

“Overall, ReSPECT supports using rezafungin for antifungal prophylaxis in allo-HSCT recipients,” he said, adding that “rezafungin can provide sustained antifungal coverage and has the potential for a simpler antifungal prophylaxis regimen vs daily oral azole plus TMP/SMX.”


*Rezafungin 400 mg loading dose on week 1 and then 200 mg on subsequent weeks, initiated after stem cell infusion

**Fluconazole 400 mg once daily or posaconazole 300 mg twice daily on day 1, then 300 mg once daily, initiated after stem cell infusion

***TMP/SMX 80/400 mg once daily, initiated after engraftment